BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 29991685)

  • 1. Diagnosis of major depressive disorder based on changes in multiple plasma neurotransmitters: a targeted metabolomics study.
    Pan JX; Xia JJ; Deng FL; Liang WW; Wu J; Yin BM; Dong MX; Chen JJ; Ye F; Wang HY; Zheng P; Xie P
    Transl Psychiatry; 2018 Jul; 8(1):130. PubMed ID: 29991685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Divergent Urinary Metabolic Phenotypes between Major Depressive Disorder and Bipolar Disorder Identified by a Combined GC-MS and NMR Spectroscopic Metabonomic Approach.
    Chen JJ; Zhou CJ; Liu Z; Fu YY; Zheng P; Yang DY; Li Q; Mu J; Wei YD; Zhou JJ; Huang H; Xie P
    J Proteome Res; 2015 Aug; 14(8):3382-9. PubMed ID: 26168936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolite signature for diagnosing major depressive disorder in peripheral blood mononuclear cells.
    Zheng P; Fang Z; Xu XJ; Liu ML; Du X; Zhang X; Wang H; Zhou J; Xie P
    J Affect Disord; 2016 May; 195():75-81. PubMed ID: 26874244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tryptophan-kynurenine and lipid related metabolites as blood biomarkers for first-episode drug-naïve patients with major depressive disorder: An exploratory pilot case-control study.
    Kuwano N; Kato TA; Setoyama D; Sato-Kasai M; Shimokawa N; Hayakawa K; Ohgidani M; Sagata N; Kubo H; Kishimoto J; Kang D; Kanba S
    J Affect Disord; 2018 Apr; 231():74-82. PubMed ID: 29454180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery and validation of plasma biomarkers for major depressive disorder classification based on liquid chromatography-mass spectrometry.
    Liu X; Zheng P; Zhao X; Zhang Y; Hu C; Li J; Zhao J; Zhou J; Xie P; Xu G
    J Proteome Res; 2015 May; 14(5):2322-30. PubMed ID: 25784130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of plasma biomarkers for distinguishing bipolar depression from major depressive disorder by iTRAQ-coupled LC-MS/MS and bioinformatics analysis.
    Ren J; Zhao G; Sun X; Liu H; Jiang P; Chen J; Wu Z; Peng D; Fang Y; Zhang C
    Psychoneuroendocrinology; 2017 Dec; 86():17-24. PubMed ID: 28910601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of metabolomics-based urinary biomarker models for recognizing major depression disorder and bipolar disorder.
    Wang T; Yang J; Zhu Y; Niu N; Ding B; Wang P; Zhao H; Li N; Chao Y; Gao S; Dong X; Wang Z
    J Affect Disord; 2024 Jul; 356():1-12. PubMed ID: 38548210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disturbance of neurotransmitter metabolism in drug-naïve, first-episode major depressive disorder: a comparative study on adult and adolescent cohorts.
    Wang L; Yang P; Yang C; Yang D; Wu X; Cao T; Zeng C; Chen Q; Zhang S; Zhu Z; Jiao S; Cai H
    Eur Arch Psychiatry Clin Neurosci; 2022 Oct; 272(7):1283-1296. PubMed ID: 35410391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolomics of Major Depressive Disorder and Bipolar Disorder: Overview and Future Perspective.
    Hashimoto K
    Adv Clin Chem; 2018; 84():81-99. PubMed ID: 29478517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma metabolome analysis of patients with major depressive disorder.
    Kawamura N; Shinoda K; Sato H; Sasaki K; Suzuki M; Yamaki K; Fujimori T; Yamamoto H; Osei-Hyiaman D; Ohashi Y
    Psychiatry Clin Neurosci; 2018 May; 72(5):349-361. PubMed ID: 29356314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential urinary metabolites related with the severity of major depressive disorder.
    Chen JJ; Zhou CJ; Zheng P; Cheng K; Wang HY; Li J; Zeng L; Xie P
    Behav Brain Res; 2017 Aug; 332():280-287. PubMed ID: 28624318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C-reactive protein: A differential biomarker for major depressive disorder and bipolar II disorder.
    Chang HH; Wang TY; Lee IH; Lee SY; Chen KC; Huang SY; Yang YK; Lu RB; Chen PS
    World J Biol Psychiatry; 2017 Feb; 18(1):63-70. PubMed ID: 26895280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel urinary metabolite signature for diagnosing major depressive disorder.
    Zheng P; Chen JJ; Huang T; Wang MJ; Wang Y; Dong MX; Huang YJ; Zhou LK; Xie P
    J Proteome Res; 2013 Dec; 12(12):5904-11. PubMed ID: 24224655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The potential biomarker panels for identification of Major Depressive Disorder (MDD) patients with and without early life stress (ELS) by metabonomic analysis.
    Ding X; Yang S; Li W; Liu Y; Li Z; Zhang Y; Li L; Liu S
    PLoS One; 2014; 9(5):e97479. PubMed ID: 24870353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brain-derived neurotrophic factor levels and bipolar disorder in patients in their first depressive episode: 3-year prospective longitudinal study.
    Li Z; Zhang C; Fan J; Yuan C; Huang J; Chen J; Yi Z; Wang Z; Hong W; Wang Y; Lu W; Guan Y; Wu Z; Su Y; Cao L; Hu Y; Hao Y; Liu M; Yu S; Cui D; Xu L; Song Y; Fang Y
    Br J Psychiatry; 2014 Jul; 205(1):29-35. PubMed ID: 24764546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differentiation between major depressive disorder and bipolar disorder by auditory steady-state responses.
    Isomura S; Onitsuka T; Tsuchimoto R; Nakamura I; Hirano S; Oda Y; Oribe N; Hirano Y; Ueno T; Kanba S
    J Affect Disord; 2016 Jan; 190():800-806. PubMed ID: 26625092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and validation of urinary metabolite biomarkers for major depressive disorder.
    Zheng P; Wang Y; Chen L; Yang D; Meng H; Zhou D; Zhong J; Lei Y; Melgiri ND; Xie P
    Mol Cell Proteomics; 2013 Jan; 12(1):207-14. PubMed ID: 23111923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma amino acid profile in major depressive disorder: Analyses in two independent case-control sample sets.
    Ogawa S; Koga N; Hattori K; Matsuo J; Ota M; Hori H; Sasayama D; Teraishi T; Ishida I; Yoshida F; Yoshida S; Noda T; Higuchi T; Kunugi H
    J Psychiatr Res; 2018 Jan; 96():23-32. PubMed ID: 28950111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative Proteomic Approach for Discriminating Major Depressive Disorder and Bipolar Disorder by Multiple Reaction Monitoring-Mass Spectrometry.
    Shin D; Rhee SJ; Lee J; Yeo I; Do M; Joo EJ; Jung HY; Roh S; Lee SH; Kim H; Bang M; Lee KY; Kwon JS; Ha K; Ahn YM; Kim Y
    J Proteome Res; 2021 Jun; 20(6):3188-3203. PubMed ID: 33960196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarkers for major depressive and bipolar disorders using metabolomics: A systematic review.
    MacDonald K; Krishnan A; Cervenka E; Hu G; Guadagno E; Trakadis Y
    Am J Med Genet B Neuropsychiatr Genet; 2019 Mar; 180(2):122-137. PubMed ID: 30411484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.